JP7850417B2 - 新規インターロイキン－２バリアントおよびその二官能性融合分子 - Google Patents

新規インターロイキン－２バリアントおよびその二官能性融合分子

Info

Publication number
JP7850417B2
JP7850417B2 JP2021573426A JP2021573426A JP7850417B2 JP 7850417 B2 JP7850417 B2 JP 7850417B2 JP 2021573426 A JP2021573426 A JP 2021573426A JP 2021573426 A JP2021573426 A JP 2021573426A JP 7850417 B2 JP7850417 B2 JP 7850417B2
Authority
JP
Japan
Prior art keywords
cells
amino acid
variant
treg
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021573426A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022536347A5 (https=
JP2022536347A (ja
JPWO2020252421A5 (https=
Inventor
リ，ユエシェン
ルイ，リンユン
ス，ジン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cugene Inc
Original Assignee
Cugene Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cugene Inc filed Critical Cugene Inc
Publication of JP2022536347A publication Critical patent/JP2022536347A/ja
Publication of JP2022536347A5 publication Critical patent/JP2022536347A5/ja
Publication of JPWO2020252421A5 publication Critical patent/JPWO2020252421A5/ja
Application granted granted Critical
Publication of JP7850417B2 publication Critical patent/JP7850417B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2021573426A 2019-06-14 2020-06-13 新規インターロイキン－２バリアントおよびその二官能性融合分子 Active JP7850417B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962861484P 2019-06-14 2019-06-14
US62/861,484 2019-06-14
PCT/US2020/037648 WO2020252421A2 (en) 2019-06-14 2020-06-13 Novel interleukin-2 variants and bifunctional fusion molecules thereof

Publications (4)

Publication Number Publication Date
JP2022536347A JP2022536347A (ja) 2022-08-15
JP2022536347A5 JP2022536347A5 (https=) 2023-08-07
JPWO2020252421A5 JPWO2020252421A5 (https=) 2023-08-07
JP7850417B2 true JP7850417B2 (ja) 2026-04-23

Family

ID=73782254

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021573426A Active JP7850417B2 (ja) 2019-06-14 2020-06-13 新規インターロイキン－２バリアントおよびその二官能性融合分子

Country Status (8)

Country Link
US (1) US20220170028A1 (https=)
EP (1) EP3983001A4 (https=)
JP (1) JP7850417B2 (https=)
KR (1) KR20220035122A (https=)
CN (1) CN114728040A (https=)
AU (1) AU2020292421B2 (https=)
CA (1) CA3143038A1 (https=)
WO (1) WO2020252421A2 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020057646A1 (zh) 2018-09-21 2020-03-26 信达生物制药(苏州)有限公司 新型白介素2及其用途
MX2022007712A (es) * 2019-12-17 2022-09-26 Amgen Inc Agonista doble de interleucina-2/receptor de tnf para uso en terapia.
US11633488B2 (en) 2020-01-10 2023-04-25 Bright Peak Therapeutics Ag Modified IL-2 polypeptides and uses thereof
JP7748393B2 (ja) 2020-05-08 2025-10-02 アルパイン イミューン サイエンシズ インコーポレイテッド Ａｐｒｉｌおよびｂａｆｆ阻害免疫調節タンパク質、ならびにその使用方法
TWI815194B (zh) 2020-10-22 2023-09-11 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
US20240199714A1 (en) * 2021-04-16 2024-06-20 Orionis Biosciences, Inc. Il-2 based constructs
WO2023281485A1 (en) * 2021-07-09 2023-01-12 Bright Peak Therapeutics Ag Modified il-2 polypeptides for treatment of inflammatory and autoimmune diseases
KR20240082364A (ko) * 2021-09-22 2024-06-10 포트비타 바이오로직스 (싱가포르) 피티이. 리미티드 인터루킨-2 돌연변이 및 이의 융합 단백질
US20240376172A1 (en) * 2021-10-06 2024-11-14 Iltoo Pharma Interleukin 2 chimeric constructs with targeting specificy to inflamed tissues
WO2023154785A2 (en) * 2022-02-10 2023-08-17 Orionis Biosciences, Inc. Il-2 trap molecules
US20250215452A1 (en) 2022-03-25 2025-07-03 Universität Zürich Adenoviral Mediated Targeting of Activated Immune Cells
CA3259108A1 (en) 2022-06-16 2023-12-21 Cephalon Llc Attenuated Anti-PD1-IL2 Immunoconjugates and Their Uses
EP4582455A4 (en) * 2022-08-29 2026-03-25 Jiangsu Hengrui Pharmaceuticals Co Ltd Fusion protein comprising a Taci polypeptide and its use
EP4689123A1 (en) * 2023-03-29 2026-02-11 WuXi Biologics Ireland Limited Il-2 variants with improved stability and compositions thereof
WO2024249568A1 (en) 2023-05-30 2024-12-05 Paragon Therapeutics, Inc. Alpha4beta7 integrin antibody compositions and methods of use
CN121889424A (zh) 2023-08-14 2026-04-17 派拉冈医疗公司 α4β7整联蛋白结合蛋白及使用方法
WO2025040797A1 (en) * 2023-08-23 2025-02-27 Depth Charge Ltd Interleukin-2 variant proteins that facilitate covalent chemical conjugation and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005511707A (ja) 2001-12-04 2005-04-28 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング 調節された選択性を有する免疫サイトカイン
US20170362321A1 (en) 2016-06-20 2017-12-21 Kymab Limited Antibodies and immunocytokines

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6955807B1 (en) * 1998-05-15 2005-10-18 Bayer Pharmaceuticals Corporation IL-2 selective agonists and antagonists
CN1930300A (zh) * 2004-03-05 2007-03-14 希龙公司 预测患者治疗药物耐受性的体外试验系统
BRPI0508470A (pt) * 2004-03-05 2007-07-31 Chiron Corp sistema de teste in vitro para prever toleráncia do paciente aos agentes terapêuticos
CN102260352B (zh) * 2010-05-28 2013-11-20 山东先声麦得津生物制药有限公司 靶向性白细胞介素融合蛋白及其制备方法与应用
HUE029139T2 (hu) * 2011-02-10 2017-02-28 Roche Glycart Ag Mutáns interleukin-2 polipeptidek
KR102042246B1 (ko) * 2014-02-06 2019-11-28 에프. 호프만-라 로슈 아게 인터류킨-2 융합 단백질 및 이의 용도
KR102379464B1 (ko) * 2016-06-20 2022-03-29 키맵 리미티드 항-pd-l1 항체
KR20190136076A (ko) * 2017-04-13 2019-12-09 에프. 호프만-라 로슈 아게 암 치료 방법에 사용하기 위한 인터루킨-2 면역접합체, cd40 작용제 및 임의적인 pd-1 축 결합 길항제
JP2020521452A (ja) * 2017-05-24 2020-07-27 パンディオン・セラピューティクス・インコーポレイテッド 標的化免疫寛容
JP2020521759A (ja) * 2017-05-26 2020-07-27 ザ・ジョンズ・ホプキンス・ユニバーシティ 免疫トレランスを調節するための多機能性の抗体−リガンド・トラップ
JP7637415B2 (ja) * 2018-06-22 2025-02-28 キュージーン インコーポレイテッド インターロイキン－２バリアントおよびその使用方法
AU2020287373B2 (en) * 2019-06-05 2026-01-29 Asher Biotherapeutics, Inc. Fusions of mutant interleukin-2 polypeptides with antigen binding molecules for modulating immune cell function

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005511707A (ja) 2001-12-04 2005-04-28 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング 調節された選択性を有する免疫サイトカイン
US20170362321A1 (en) 2016-06-20 2017-12-21 Kymab Limited Antibodies and immunocytokines

Also Published As

Publication number Publication date
WO2020252421A3 (en) 2021-01-21
CA3143038A1 (en) 2020-12-17
CN114728040A (zh) 2022-07-08
AU2020292421A1 (en) 2022-01-27
EP3983001A2 (en) 2022-04-20
KR20220035122A (ko) 2022-03-21
JP2022536347A (ja) 2022-08-15
EP3983001A4 (en) 2023-10-04
WO2020252421A2 (en) 2020-12-17
AU2020292421B2 (en) 2026-01-08
US20220170028A1 (en) 2022-06-02

Similar Documents

Publication Publication Date Title
JP7850417B2 (ja) 新規インターロイキン－２バリアントおよびその二官能性融合分子
JP7827324B2 (ja) インターロイキン－２バリアントおよびその使用方法
JP7607938B2 (ja) がんの治療ための新規インターロイキン－２バリアント
CN115151279A (zh) 基于细胞因子的可生物活化药物及其使用方法
RU2833537C2 (ru) Новые варианты интерлейкина-2 для лечения рака
RU2819307C2 (ru) Биологически активируемые лекарственные средства на основе цитокинов и способы их применения
WO2024054424A1 (en) Novel pd1-targeted il-2 immunocytokine and vitokine fusions
HK40074638B (zh) 用於癌症治疗的新型白介素-2变体
HK40074638A (en) Novel interleukin-2 variants for the treatment of cancer

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230612

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230728

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240604

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240827

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241030

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241204

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250212

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250508

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250702

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250804

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251007

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260107

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260310

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260406